[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rousselot BVBA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,68,93,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622819","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-function-at-varying-dosages-in-healthy-younger-adults-with-self-reported-attention-problems-100622819",false,"NCT07388576","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof-of-concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","Inclusion Criteria:\n\n1. Males and females 18-39 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported focus or attention problems, as determined by QI assessment of the Adult Attention Deficit Hyperactivity Disorder Self-Report Scale (Part A) (ASRS; version 1.1) (20)\n4. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n5. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n6. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n7. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n8. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n9. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n10. Provided voluntary, written, informed consent to participate in the study\n11. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Clinical diagnosis and\u002For prescribed treatment for ADHD (See Section 7.3.1)\n4. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., autism spectrum disorder, schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n5. Self-reported color blindness\u002Fweakness as assessed by the QI\n6. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n7. Current employment that calls for overnight shiftwork as assessed by the QI\n8. Unstable metabolic disease or chronic diseases as assessed by the QI\n9. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n10. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n11. Type I diabetes\n12. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n13. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n14. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n15. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n21. Use of medical cannabinoid products\n22. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n23. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n24. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n25. Alcohol or drug abuse within the last 12 months\n26. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n27. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n28. Clinically significant abnormal laboratory results at screening as assessed by the QI\n29. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n30. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n31. Individuals who are cognitively impaired and\u002For unable to give informed consent\n32. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,"ALL","18 Years","39 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive function at varying dosages in healthy younger adults with self-reported attention problems.\n\nThe main question it aims to answer is what Change from baseline to Day 56 between AP-Brain (1g, 3g, or 5g) and placebo in cognitive function, as assessed by the CNS VS Neurocognitive Index (NCI) score and complex attention.\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[28,29],"Cognition","Cognitive Function",[31,32,33],"memory","cognitive function","AP-Brain","RECRUITING","2026-06-19",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2026-11",{"name":44,"class":45},"Rousselot BVBA","INDUSTRY",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":46},"100622778","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-performance-at-varying-dosages-in-healthy-middle-aged-and-older-adults-with-self-reported-memory-problems-100622778","NCT07388043","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof of Concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","Inclusion Criteria:\n\n1. Males and females 40-79 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported memory problems as assessed by a combined score of ≥6 from the memory assessment questions provided at screening\n4. Absence of dementia or other significant cognitive impairment as assessed by MMSE-2 score of ≥24 at screening\n5. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n6. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n7. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n8. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n9. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n10. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n11. Provided voluntary, written, informed consent to participate in the study\n12. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., attention-deficit\u002Fhyperactivity disorder, Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n4. Self-reported color blindness\u002Fweakness as assessed by the QI\n5. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n6. Current employment that calls for overnight shiftwork as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n10. Type I diabetes\n11. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n16. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n17. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n18. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n19. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n20. Use of medical cannabinoid products\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n26. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n27. Clinically significant abnormal laboratory results at screening as assessed by the QI\n28. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n29. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n30. Individuals who are cognitively impaired and\u002For unable to give informed consent\n31. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","40 Years","79 Years",{"count":21,"type":22},[25],"The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive performance at varying dosages in healthy middle-aged and older adults with self-reported memory problems. The main question it aims to answer is:\n\nWhat is the effect of AP-Brain at 1 g, 3 g, and 5 g on cognitive performance?\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[28,60],"Cognitive Performance",[62,33,63],"Memory","cognitive performance",{"date":37,"type":38},{"date":40,"type":22},{"date":42,"type":22},{"name":44,"class":45},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100638248","cp-intestinal-permeability-100638248","NCT07586930","CP: Intestinal Permeability","Effects of Collagen Peptide on Intestinal Permeability Following an Acute Aspirin Challenge in Adults With Moderate GI Symptoms: a Double-blind, Placebo-controlled, Randomised Study.","Inclusion Criteria:\n\n1. Be able to give written informed consent.\n2. Be between 18-65 years (inclusive)\n3. Gastrointestinal symptoms confirmed by an average GSRS-IBS score between ≥2.5 and ≤4.5 at Visit 1 and Visit 2 (+0.5).\n4. If Participant has used aspirin in the past and they have not experienced adverse events.\n5. Willing to avoid alcohol consumption 2 days prior to each permeability test.\n6. Willing to refrain from lactulose, sugar substitutes, and sucralose or mannitol-containing products, for 24-hours prior to the urine collection period.\n7. Willing to consume the study product daily for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n2. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:\n\n   1. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).\n   2. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.\n   3. Sexual partner(s) is\u002Fare exclusively female.\n   4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.\n   5. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.\n3. DASS-21 Depression score of \\>21 at screening.\n4. Has a history of drug and\u002For alcohol abuse. (Drinks more than nationally recommended units per week (\\>11 units for women; \\>17 units for men); alcohol\u002Fsubstance abuse disorder).\n5. Has food allergies or other issues with foods that would preclude intake of the Study Products\n6. Lactose intolerance\n7. Vegetarians not willing to consume animal-based food supplement.\n8. Intolerant to aspirin.\n9. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n   1. Diagnosed gastrointestinal condition\n   2. Severe or uncontrolled cardiovascular disease\n   3. Severe renal disease\u002F renal impairment\n   4. Liver disease\n   5. Diabetes\n   6. Any known bleeding disorder\n10. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n    1. Medications affecting gut\u002Fintestinal motility (2 weeks prior to visit 1)\n    2. Daily usage of non-steroidal anti-inflammatory drugs (NSAIDs) in the last 2 months or incidental use in the last 2 weeks prior to screening\n    3. Antibiotics (4 weeks prior to visit 1)\n11. Current or recent (in the past 4-weeks) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited supplements include:\n\n    1. Collagen supplements (e.g., for bone and joint health and\u002For skin)\n    2. Supplements effecting gut motility (e.g. iron, magnesium citrate)\n    3. Cannabidiol or hemp containing products or supplements\n    4. Probiotics\n    5. Prebiotics\n    6. Postbiotics\n12. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n13. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.","65 Years",{"count":77,"type":22},92,[25],"The goal of this clinical trial is to evaluate the effects of 45 days daily administration of three different doses (2.5g, 5g, and 10g) of collagen peptide in healthy adults as compared to a Placebo on intestinal permeability following an acute aspirin challenge. The main question it aims to answer is change from Day 42 to Day 45 following an acute aspirin challenge (NSAID) between three different doses (2.5g, 5g, and 10g) of collagen peptide, respectively as compared to a Placebo on intestinal permeability measured by the urinary lactulose : mannitol ratio (test collected over a period of 5 hours).",[81],"Intestinal Permability",[83],"intestinal permability","2026-05-22",{"date":86,"type":38},"2026-05-27",{"date":88,"type":38},"2026-03-25",{"date":90,"type":22},"2026-11-23",{"name":44,"class":45},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":17,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100636942","a-clinical-trial-to-assess-the-effect-of-ap-brain-collagen-peptides-on-the-improvement-of-attention-focus-and-memory-in-stressed-but-otherwise-healthy-individuals-100636942","NCT07572240","A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals","A Randomized, Open-Label, Parallel Proof-of-Concept Study to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals","Inclusion Criteria:\n\n* Individuals ready to give voluntary, written informed consent to participate in the study.\n* Male and female individuals of age between 35 to 70 years (both values included).\n* Individuals with body mass index (BMI) between 18.5 kg\u002Fm\\^2 to 29.9 kg\u002Fm\\^2 (both values included).\n* Perceived Stress Scale (PSS) scores between 14 to 26 (both values included).\n* Individuals with mild cognitive impairment as indicated by Addenbrooke's Cognitive Examination (ACE) III scores between 75 to 88 (both values included).\n* Self-reported mild difficulties in focus, attention, or memory.\n* Progressive cognitive complaints like stress, disturbed sleep etc. reported by participant.\n* Individuals willing to consume an investigational product from bovine source.\n* Individuals willing to complete all study-related and clinical study visits as per protocol.\n\nExclusion Criteria:\n\n* Clinically diagnosed with Attention Deficit Hyperactivity Disorder (ADHD).\n* Clinically diagnosed with mental disorders (diagnostic and statistical manual of mental disorders: DSM-5-TR), namely but not limited to epilepsy, anxiety, depression or Alzheimer's disease.\n* Individuals with a medical history of cardiac disease, respiratory disorders, kidney disorder, liver disorder, or seizure disorders or other chronic health conditions requiring medication.\n* Individuals with uncontrolled hypertension (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg).\n* Individuals with uncontrolled diabetes (fasting blood glucose (FBG) greater than equal to 126 mg\u002Fdl).\n* Individuals with history of hypersensitivity to any components of the investigational product.\n* Those taking prescription medication or dietary supplements that affect cognitive function within 30 days prior to screening.\n* Head injury immediately preceding cognitive deterioration.\n* Consumption of excessive amounts of caffeine (more than 4-5 cups per day) and caffeine-containing foods or beverages.\n* Current smokers.\n* Those who are deemed unable to comply with the test requirements or otherwise deemed unsuitable according to the Investigator's opinion.\n* Females who are pregnant\u002Fplanning to be pregnant\u002Flactating or taking any oral contraceptives.\n* History of drug or alcohol addiction or abuse with the past 12 months.","35 Years","70 Years",{"count":103,"type":22},72,[25],"The goal of this clinical trial is to learn about the effects of AP-Brain collagen peptide on attention, focus, and memory in adults who are stressed but otherwise healthy.\n\nThe main questions it aims to answer are:\n\n* How does AP-Brain affect a participant's attention, focus, stress, and memory?\n* Is there a difference in the effects between a higher dose and a lower dose?\n* What are the side effects, if any, for participants taking AP-Brain?\n\nResearchers will compare two different doses of AP-Brain to see how they affect brain function and stress levels.\n\nParticipants in this study will be asked to:\n\n* Take one of two the doses of AP-Brain once a day for 56 days.\n* Visit the study center for regular checkups.\n* Complete tasks that measure memory, focus, and attention.\n* Answer survey questions about their stress levels.\n* Provide blood samples and have vital signs checked.\n* Have the brain's response to tasks monitored to see how it affects attention and alertness.",[107,108],"Healthy","Stress",[110,62,111,112],"Collagen Peptides","Attention","Focus","NOT_YET_RECRUITING","2026-05-06",{"date":116,"type":38},"2026-05-11",{"date":118,"type":22},"2026-05-18",{"date":120,"type":22},"2026-10",{"name":44,"class":45},9,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":92},"100604403","effect-of-chronic-exposure-to-nextida-gc-b-on-glycemic-control-in-adults-with-normoglycemia-or-prediabetes-100604403","NCT07149064","Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes","Inclusion Criteria:\n\n1. Males and females 18 years and older\n2. BMI of 25 to 34.9 kg\u002Fm2, inclusive\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   2. Double-barrier method\n   3. Intrauterine devices\n   4. Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   5. Vasectomy of partner at least 6 months prior to screening\n   6. Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Individuals with normoglycemia (HbA1c ≤5.9%) or prediabetes (HbA1c 6.0 to ≤6.4%) at screening\n5. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the Qualified Investigator (QI)\n6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, and skin, nail and hair habits) as much as possible throughout the study\n7. Willingness to complete questionnaires, records and diaries associated with the study, comply with continuous glucose monitor (CGM) device instructions, and complete all clinic visits\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history and laboratory results as assessed by QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product, placebo or standardized meal ingredients\n3. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n4. Poor venous access as assessed by the QI\n5. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n6. Unstable metabolic disease or chronic diseases as assessed by the QI\n7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n9. Type I or Type II diabetes\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n16. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n17. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n18. Use of medical cannabinoid products\n19. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n20. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n21. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n22. Alcohol or drug abuse within the last 12 months\n23. Clinically significant abnormal laboratory results at screening as assessed by the QI\n24. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n25. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n26. Individuals who are unable to give informed consent\n27. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":131,"type":22},60,[25],"The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is:\n\nWhat is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).",[135,136,137],"Normoglycemia","Prediabetes","Glycemic Control",[139,140,141,136,142],"Nextida GC-B","glycemic control","normoglycemia","postprandial glycemic control","2026-03-12",{"date":145,"type":38},"2026-03-16",{"date":147,"type":38},"2026-02-18",{"date":149,"type":22},"2026-08",{"name":44,"class":45},""]